IRIS
VICENTI, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.175
AS - Asia 1.002
EU - Europa 342
SA - Sud America 218
Continente sconosciuto - Info sul continente non disponibili 97
AF - Africa 54
OC - Oceania 1
Totale 2.889
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.063
IT - Italia 294
BD - Bangladesh 242
CN - Cina 227
SG - Singapore 198
BR - Brasile 136
HK - Hong Kong 118
VN - Vietnam 78
CA - Canada 50
IN - India 33
AR - Argentina 28
MX - Messico 27
IQ - Iraq 18
EC - Ecuador 17
PK - Pakistan 16
ID - Indonesia 13
ZA - Sudafrica 13
CO - Colombia 11
SA - Arabia Saudita 11
RU - Federazione Russa 10
CL - Cile 9
TR - Turchia 9
CR - Costa Rica 8
UZ - Uzbekistan 8
VE - Venezuela 8
MA - Marocco 7
PH - Filippine 7
PY - Paraguay 7
PL - Polonia 6
TN - Tunisia 6
MY - Malesia 5
EG - Egitto 4
ES - Italia 4
FR - Francia 4
GB - Regno Unito 4
IL - Israele 4
CH - Svizzera 3
CU - Cuba 3
DE - Germania 3
DZ - Algeria 3
HN - Honduras 3
JM - Giamaica 3
NL - Olanda 3
PR - Porto Rico 3
AT - Austria 2
BB - Barbados 2
BZ - Belize 2
CG - Congo 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GT - Guatemala 2
IE - Irlanda 2
JO - Giordania 2
MR - Mauritania 2
NE - Niger 2
NI - Nicaragua 2
SN - Senegal 2
TH - Thailandia 2
UA - Ucraina 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BE - Belgio 1
BH - Bahrain 1
BS - Bahamas 1
CD - Congo 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GN - Guinea 1
GP - Guadalupe 1
HR - Croazia 1
JP - Giappone 1
KE - Kenya 1
KR - Corea 1
KZ - Kazakistan 1
LB - Libano 1
LC - Santa Lucia 1
LT - Lituania 1
LY - Libia 1
ME - Montenegro 1
MU - Mauritius 1
NG - Nigeria 1
PA - Panama 1
PE - Perù 1
PG - Papua Nuova Guinea 1
PS - Palestinian Territory 1
SD - Sudan 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
TZ - Tanzania 1
UG - Uganda 1
UY - Uruguay 1
Totale 2.792
Salva come PNG Salva come JPEG
Città #
San Jose 364
Ashburn 212
Beijing 125
Hong Kong 114
Council Bluffs 96
Singapore 90
Santa Clara 49
Milan 43
New York 35
Ho Chi Minh City 30
Rome 26
Phoenix 20
Chicago 19
Mexico City 19
Naples 18
Los Angeles 14
Figino 11
Hanoi 11
Bari 10
São Paulo 9
Toronto 9
Turin 9
Baghdad 8
Buffalo 8
Catania 8
Tashkent 8
Bologna 7
Rio de Janeiro 7
Riyadh 7
Salvador 7
Atlanta 6
Biên Hòa 6
Brasília 6
Brescia 6
Mumbai 6
Quito 6
Bogotá 5
Casablanca 5
North Bergen 5
San José 5
Thái Bình 5
Charlotte 4
Chennai 4
Dallas 4
Guarulhos 4
Guayaquil 4
Houston 4
Ningbo 4
Padua 4
Palermo 4
Asunción 3
Belo Horizonte 3
Cagliari 3
Cairo 3
Campinas 3
Can Tho 3
Delhi 3
Detroit 3
Dietikon 3
Durban 3
Florence 3
Haiphong 3
Havana 3
Istanbul 3
Itaquaquecetuba 3
Jeddah 3
Johannesburg 3
Medellín 3
Miami 3
Montreal 3
Ninh Bình 3
Orem 3
Pretoria 3
Seattle 3
Shanghai 3
Taboão da Serra 3
Venice 3
Ahmedabad 2
Ambato 2
Amman 2
Barcelona 2
Bengaluru 2
Bridgetown 2
Burnaby 2
Bình Dương 2
Calgary 2
Camaçari 2
Cape Town 2
Caracas 2
Cary 2
Chula Vista 2
Cuenca 2
Curitiba 2
Córdoba 2
Da Nang 2
Dakar 2
Denpasar 2
Denver 2
Dublin 2
El Cajon 2
Totale 1.617
Salva come PNG Salva come JPEG
Nome #
Neutralizing activity of African lineage Zika virus immune sera towards Asian lineage 99
SARS-CoV-2 Infection of Human Ovarian Cells: A Potential Negative Impact on Female Fertility 86
Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization 75
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 73
Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization 67
Cellular and Molecular Mechanisms of In Vivo and In Vitro SARS-CoV-2 Infection: A Lesson from Human Sperm 47
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 44
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 43
Nucleoside Derivatives of 2,6-Diaminopurine Antivirals: Base-Modified Nucleosides with Broad-Spectrum Antimicrobial Properties 41
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 41
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 40
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 39
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 38
Switching the three-component Biginelli-like reaction conditions for the regioselective synthesis of new 2-amino[1,2,4]triazolo[1,5-a]pyrimidines 38
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 38
Analysis of the SARS-CoV-2 inactivation mechanism using violet-blue light (405 nm) 37
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro 37
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 35
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants 35
HIV-1 Integrase Inhibition Activity by Spiroketals Derived from Plagius flosculosus, an Endemic Plant of Sardinia (Italy) and Corsica (France) 35
Genomic epidemiology of the main SARS-CoV-2 variants in Italy between summer 2020 and winter 2021 34
Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes 34
Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection 34
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose 34
SARS-CoV-2 infection of human ovarian cells: an in vitro model for the detection of the virus entry into the host cells 34
Analysis of genetic and viral determinants of HBsAg levels in patients with chronic HBV infection 33
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice 33
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro 33
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients 32
Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort 32
Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P3 32
Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020 32
Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing 32
BNT162b2 SARS-CoV-2 vaccination elicits high titers of neutralizing antibodies to both b.1 and p.1 variants in previously infected and uninfected subjects 32
Serendipitous identification of azine anticancer agents using a privileged scaffold morphing strategy 31
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 31
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 31
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 31
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 30
Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria 30
Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype 30
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 30
Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients 30
Bithiazole Inhibitors of Phosphatidylinositol 4-Kinase (PI4KIIIβ) as Broad-Spectrum Antivirals Blocking the Replication of SARS-CoV-2, Zika Virus and Human Rhinoviruses 29
Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 28
Time Course of Neutralizing Antibody in Health Care Workers With Mild or Asymptomatic COVID-19 Infection 28
Zika Virus Epidemiology in Selected West African Countries between 2007 and 2012 28
Molecular Tracing of SARS-CoV-2 in Italy in the First Three Months of the Epidemic 27
Hepatitis B virus vaccination in HIV-1-infected young adults: A tool to reduce the size of HIV-1 reservoirs? 27
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 27
Long-Term Longitudinal Analysis of Neutralizing Antibody Response to Three Vaccine Doses in a Real-Life Setting of Previously SARS-CoV-2 Infected Healthcare Workers: A Model for Predicting Response to Further Vaccine Doses 27
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2 27
Zika virus in west africa: A seroepidemiological study between 2007 and 2012 27
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 27
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 26
Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors 26
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 26
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy 25
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 25
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 25
Circulating SARS-CoV-2 variants in Italy, October 2020-March 2021 25
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 25
SARS-CoV-2 and influenza virus coinfections in the Tuscan population during the 2021/2022 influenza season 25
Unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 25
Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination 24
Surveillance for severe acute respiratory infections among hospitalized subjects from 2015/2016 to 2019/2020 seasons in Tuscany, Italy 23
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 23
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 23
SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19 22
Use of peripheral blood DNA for genotypic antiretroviral resistance testing in drug-naïve HIV-infected subjects 22
Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection 22
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge 22
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting 22
Rules-based HIV-1 genotypic resistance interpretation systems predict 8-week and 24-week virological antiretroviral treatment outcome and benefit from drug potency weighting 22
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors 22
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication 21
Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity 21
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 21
Piperazine-derived small molecules as potential Flaviviridae NS3 protease inhibitors. In vitro antiviral activity evaluation against Zika and Dengue viruses 21
The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects 20
Impact of remote vs. local sampling on sensitivity of genotypic antiretroviral resistance testing 20
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 20
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 20
Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania 20
Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database 20
SARS-CoV2 infection in human testis and sperm: in vivo and in vitro studies 20
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 20
Incorporating temporal dynamics of mutations to enhance the prediction capability of antiretroviral therapy’s outcome for HIV-1 19
Serum neutralizing activity against b.1.1.7, b.1.351, and p.1 sars-cov-2 variants of concern in hospitalized covid-19 patients 18
Impact of DNA-stored mutations on virological response in virologically suppressed PWH in the switch to modern regimens 17
Harnessing prebiotic formamide chemistry: a novel platform for antiviral exploration 15
SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy 15
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies 13
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 12
Genomic Epidemiology of the Main SARS-CoV-2 Variants Circulating in Italy During the Omicron Era 11
Totale 2.889
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.506
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.506
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/20254 0 0 0 1 0 0 0 1 0 1 0 1
2025/20262.149 83 15 218 143 141 103 54 108 574 234 250 226
2026/2027736 163 51 215 307 0 0 0 0 0 0 0 0
Totale 2.889